Chitosan-based DDSs for pH/hypoxia dual-triggered DOX delivery: Facile morphology modulation for higher in vitro cytotoxicity

Fluorescent folic acid-chitosan/carbon dot for pH-responsive drug delivery and bioimaging

Nowadays, one of the most important reasons of death in the world is cancer. With the development of nanotechnology, advanced methods for treatment of cancer have introduced. In this work, the fluorescent carbon dots (CDs) were prepared from chitosan as the second abundant polysaccharide present in the nature. The surface of CDs was modified with chitosan (CDs/CS) and then the amino groups of chitosan were conjugated with activated folic acid (CDs/CS-FA) for controlled delivery of doxorubicin (DOX) as anticancer drug against HeLa cancer cells. The DOX loading efficiency of fluorescent CDs/CS-FA was high and nearly 60 %. Due to pH sensitive swelling/deswelling of CS, the percentage of cumulative DOX release could reach 90 % at cancer tissue (pH of 5.0) and 52 % at normal tissue (pH of 7.4) within 30 h. The cytotoxicity study revealed that the synthesized CDs were highly compatible on HeLa cells with cell viability 97-88 %. Cellular imaging shows that the entry of CDs/CS-FA to HeLa cells causes a green fluorescence, while the CDs/CS without FA have a negligible fluorescence. These results are due to the important role of FA in cell internalization. Thus, the CDs/CS-FA nanocarrier is suitable candidate for controlled pH sensitive drug delivery and cellular imaging.

Fabrication of biocompatible magnetic maltose/MIL-88 metal-organic frameworks decorated with folic acid-chitosan for targeted and pH-responsive controlled release of doxorubicin

Recently, metal-organic frameworks (MOFs) have attracted tremendous attention as promising porous drug delivery systems for cancer treatment. In this work, for the first time, a novel magnetic maltose disaccharide molecule modified with MIL-88 metal-organic framework (Fe₃O₄@C@MIL-88) was prepared, and then this targeted system was used for the delivery of the doxorubicin (DOX) drug. Eventually, Fe₃O₄@C@MIL-88-DOX were successfully decorated with folic acid conjugated chitosan (Fe₃O₄@C@MIL-88-DOX-FC) as a new targeted and controlled release drug system for treatment of MCF-7 breast cancer. The encapsulation efficiency of the DOX in the Fe₃O₄@C@MIL-88 was obtained at ∼83.6%. The in vitro drug release profiles showed a pH-responsive controlled release of DOX in acidic pH confirming the performance of the systems in the cancerous environment. The DOX release mechanism from systems at pH 5 also showed that the kinetic data well fitted to the Korsmeyer-Peppas and Fickian diffusion. Furthermore, in vitro cytotoxicity and DAPI staining study clearly illustrated that the synthesized Fe₃O₄@C@MIL-88 system had low cytotoxicity and good biocompatibility against MCF-7 cancer cells and MCF-10A normal cells. Whereas, Fe₃O₄@C@MIL-88-DOX and Fe₃O₄@C@MIL-88-DOX-FC exhibited good antitumor activity as a result of targeted delivery of DOX, which indicated the MCF-7 cell death with apoptotic effects. Based on these findings, the resulting carriers could be used as promising targeted drug delivery systems for cancer therapy.

Construction of reduction-sensitive heterodimer prodrugs of doxorubicin and dihydroartemisinin self-assembled nanoparticles with antitumor activity

Doxorubicin (DOX) is used as a first-line chemotherapeutic drug, whereas dihydroartemisinin (DHA) also shows a certain degree of antitumor activity. Disulfide bonds (-SS-) in prodrug molecules can be degraded in highly reducing environments. Thus, heterodimer prodrugs of DOX and DHA linked by a disulfide bond was designed and subsequently prepared as reduction-responsive self-assembled nanoparticles (DOX-SS-DHA NPs). In an in vitro release study, DOX-SS-DHA NPs exhibited reduction-responsive activity. Upon cellular evaluation, DOX-SS-DHA NPs were found to have better selectivity toward tumor cells and less cytotoxicity to normal cells. Compared to free DiR, DOX-SS-DHA NPs showed improved accumulation at the tumor site and even had a longer clearance half-life. More importantly, DOX-SS-DHA NPs possessed a much higher tumor inhibition efficacy than DOX-sol and MIX-sol in 4T1 tumor-bearing mice. Our results suggested the superior antitumor efficacy of DOX-SS-DHA NPs with less cytotoxicity.